Liquidia Shares Rocket After $380.7 Million Deal Ends United Therapeutics Patent War
Liquidia (LQDA) shares surged 51% in after-hours trading after a $380.7M settlement with United Therapeutics (UTHR) ended a patent dispute, allowing continued sales of its YUTREPIA drug. The payment is structured over 2026-2027, with LQDA expecting to fund it from operations and cash reserves. Analysts reacted with mixed price target adjustments.
How this was made
The 30-second read
Why it matters
The settlement removes litigation risk, prompting a sharp price jump for Liquidia while providing a cash infusion to United Therapeutics. Analysts upgraded Liquidia, reflecting a re‑rating of its risk profile.
Market read
The settlement is a material corporate event with a large cash component and a >40% stock move, making it highly relevant for traders.
What to watch
Future FDA approvals for pipeline assets and competitive pressures in PAH therapy could moderate the rally.
Background
Liquidia and United Therapeutics had been embroiled in six patent lawsuits over inhaled treprostinil formulations. The settlement resolves all claims and includes a structured payment plan.
Ticker impact
Liquidia announced a $380.7 million settlement ending its patent war with United Therapeutics, triggering a 51% after‑hours price surge.
upward pressure as risk premium is stripped, tempered by cash‑payment drag
Settlement eliminates litigation uncertainty that had depressed the stock; analysts upgraded to Buy, but the payment schedule may limit upside.
United Therapeutics received $380.7 million from Liquidia in settlement; its share price was little changed after hours.
stable to slight upside as cash improves balance sheet
The settlement amount is modest relative to United Therapeutics' market cap and did not move the stock.
Market effects
Clears a major legal hurdle for a niche pulmonary‑hypertension drug, potentially boosting biotech sector sentiment.
U.S. biotech market sees a fresh catalyst; limited broader market effect.
Settlement may influence other biotech patent disputes globally.
Counterpoint
The cash burden could strain Liquidia's balance sheet, limiting long‑term upside despite the short‑term rally.
Key entities
- companyLiquidia Corporation
Biopharmaceutical company developing inhaled therapies for pulmonary hypertension.
- companyUnited Therapeutics Corporation
Medical device and biotech firm holding patents on treprostinil formulations.
